EU/UK Regulator Round-up: 20 July 2026
This EU/UK regulator round-up for mid-July 2026 pulls only from EMA and MHRA/GOV.UK notices. The week’s densest items are PRAC’s contraceptive and Litfulo safety communications, MHRA’s 21 July lower-carbon Clenil Modulite approval, and reinforced botulinum toxin type A warnings after rare botulism cases.
Contents10 sections
Key Takeaways
- PRAC (6–9 July 2026) agreed a DHPC on meningioma risk with prolonged desogestrel or etonogestrel contraceptive use and estimated one extra meningioma per 67,300 women using the medicines.
- The same PRAC meeting agreed stronger serious-risk warnings for Litfulo (ritlecitinib), aligning it with other JAK inhibitors.
- On 21 July 2026, MHRA approved Clenil Modulite 100 mcg and 200 mcg versions using propellant HFA-152a, calling it a world-first pMDI authorisation with that propellant.
- On 15 July 2026, MHRA strengthened warnings for all botulinum toxin type A products after rare iatrogenic botulism reports.
July 2026 EU/UK notices at a glance
| Date | Regulator | Action |
|---|---|---|
| 6–9 July 2026 | EMA PRAC | Contraceptive meningioma DHPC; Litfulo warning update |
| 7 July 2026 | EMA CHMP | Phased review started for daraxonrasib in metastatic pancreatic cancer |
| 15 July 2026 | MHRA | Stronger botulinum toxin type A botulism warnings |
| 21 July 2026 | MHRA | Clenil Modulite HFA-152a lower-carbon inhaler approval |
What safety steps did PRAC take on contraceptives?
EMA’s 10 July 2026 meeting highlights cover the Pharmacovigilance Risk Assessment Committee session of 6–9 July 2026. PRAC agreed a direct healthcare professional communication on a small increased risk of meningioma with current, prolonged use (more than one year) of desogestrel- or etonogestrel-containing contraceptives, according to EMA's PRAC 6-9 July 2026 meeting highlights.
EMA says the overall likelihood of meningioma remains very low, with one additional meningioma estimated for every 67,300 women who use the medicines. Use is now contraindicated in women who have, or have had, a meningioma. Product information will list meningioma as a side effect with frequency “not known,” plus new contraindications and warnings.
PRAC based the recommendations on a large French epidemiological study that found a small increased intracranial meningioma risk with desogestrel use of one year or more, rising with longer duration. Prior use of other progestogens already linked to meningioma should be considered before starting desogestrel or etonogestrel.
What changed for Litfulo after the July PRAC?
At the same meeting, PRAC agreed a DHPC stating that warnings on potential serious side effects with the JAK inhibitor Litfulo (ritlecitinib) will be strengthened. EMA says other JAK inhibitors show increased risks of cardiovascular problems, blood clots, cancer, and serious infections, and that this increased risk is also considered to apply to Litfulo.
A boxed warning will say Litfulo should be used in certain higher-risk patients only if no suitable alternatives are available: people aged 65 or above, those at increased major cardiovascular risk, current or long-term past smokers, and those at increased cancer risk. Caution is also advised in patients with venous thromboembolism risk factors beyond those groups.
For EU label owners and affiliates, the operational follow-up is the agreed DHPC dissemination plan and national register publication, not a new initial marketing authorisation.
Why did MHRA highlight lower-carbon Clenil inhalers?
On 21 July 2026, MHRA approved new versions of Clenil Modulite 100 micrograms and 200 micrograms inhalers containing beclometasone dipropionate for maintenance asthma treatment in adults and children, per MHRA's 21 July 2026 Clenil Modulite approval notice.
MHRA said the approval is the world’s first authorisation of pressurised metered-dose inhalers using next-generation propellant HFA-152a. The propellant is not an active medicine; it delivers the inhaled dose. Active ingredient, recommended doses, and therapeutic indications are unchanged. Current Clenil Modulite versions remain available while the new versions are expected later in 2026.
The variation was granted to Chiesi Limited. Julian Beach, MHRA Executive Director of Healthcare Quality and Access, framed the decision as innovation that can support patient care and environmental sustainability without lowering quality, safety, or effectiveness standards.
How did MHRA tighten botulinum toxin communications?
On 15 July 2026, MHRA said it is strengthening safety warnings for all botulinum toxin type A products after reports of rare botulism linked to their use, according to MHRA's 15 July 2026 botulinum toxin warning. In very rare cases, toxin effect may spread beyond the injection site and cause botulism.
MHRA worked with manufacturers to update product information, including patient leaflets, to highlight iatrogenic botulism more clearly. Patients should seek immediate medical attention for difficulty swallowing, slurred speech, breathing difficulties, or muscle weakness. Symptoms can appear within days or up to four weeks after treatment.
MHRA also warned about unlicensed and counterfeit products outside regulated supply chains. Botulinum toxin type A remains a prescription-only medicine in the UK for licensed medical uses; cosmetic users are told to choose appropriately qualified practitioners and authorised products.
What else did EMA open in early July?
On 7 July 2026, EMA said CHMP had started a phased review of daraxonrasib for metastatic pancreatic cancer, based on phase 3 data versus chemotherapy in previously treated patients, per EMA's 7 July 2026 daraxonrasib phased-review notice. EMA cited life expectancy of about six months after progression and high unmet need.
The applicant is Revolution Medicines. Daraxonrasib received orphan designation for pancreatic cancer on 20 April 2026 (EU/3/26/3227). EMA positions the review as an example of phased-assessment tools expected under reformed EU pharmaceutical legislation, while stressing that quality, safety, and efficacy standards remain unchanged.
Related NovaPharma reading: PRAC June 2026 highlights, EU Commission and EMA 2026 drug report, and Vanda EMA orphan opinion coverage.
What this round-up does not claim
This brief does not reprint trade-press roundups or unverified competitor lists. It also does not treat CHMP’s July 20–23, 2026 meeting agenda as completed opinions; outcomes should wait for EMA’s post-meeting highlights. Final Commission decisions, UK SmPC publication timing for the new Clenil versions, and national DHPC roll-out dates may still move after these notices.
Frequently Asked Questions
What did PRAC decide in its 6-9 July 2026 meeting?
EMA's 10 July 2026 PRAC highlights say the committee agreed new safety information on desogestrel- and etonogestrel-containing contraceptives, including a meningioma risk warning and contraindications, and agreed stronger JAK-inhibitor-style warnings for Litfulo (ritlecitinib).
What did MHRA approve on 21 July 2026 for asthma?
MHRA approved new versions of Clenil Modulite 100 micrograms and 200 micrograms inhalers using the next-generation propellant HFA-152a. MHRA called this the world's first authorisation of pressurised metered-dose inhalers using that propellant. Availability in the UK is expected later in 2026.
Why did MHRA update botulinum toxin warnings in July 2026?
On 15 July 2026, MHRA said it is strengthening safety warnings for all botulinum toxin type A products after rare cases of botulism linked to their use. Patients should seek urgent care for symptoms such as difficulty swallowing, slurred speech, breathing problems, or muscle weakness within days to four weeks after treatment.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
